Blood grouping by molecular genetics

Authors


  • 2A-E1.3

Geoff Daniels, PhD FRCPath, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, North Bristol Park, 500 Northway, Filton, Bristol, BS34 7QH, UK
E-mail: geoff.daniels@nhsbt.nhs.uk

Abstract

It is possible to predict most clinically important blood group phenotypes from genomic DNA. Clinical applications include the following: determining foetal blood group to assess risk of haemolytic disease of the foetus and newborn or whether the pregnant woman requires antenatal anti-D prophylaxis; testing multiply transfused and autoimmune haemolytic anaemia patients; defining D variants; detecting donors with very weak D antigens; testing donors and patients when appropriate antisera are not available; RHD zygosity testing; zygosity testing of panel cells; assisting in solving difficult serological problems; and, with the use of high-throughput technologies, extended blood grouping of donors. Over the last 7 years, ISBT Workshops have provided external quality assurance. Future technologies may involve matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and massively parallel (next generation) sequencing.

Ancillary